Corneal neovascularization.
Nicholas MP, Mysore N.
Exp Eye Res. 2021 Jan;202:108363. doi: 10.1016/j.exer.2020.108363. Epub 2020 Nov 19.
Corneal neovascularization: updates on pathophysiology, investigations & management.
Sharif Z, Sharif W.
Rom J Ophthalmol. 2019 Jan-Mar;63(1):15-22.
Corneal neovascularization.
Chang JH, Gabison EE, Kato T, Azar DT.
Curr Opin Ophthalmol. 2001 Aug;12(4):242-9. doi: 10.1097/00055735-200108000-00002.
Inflammatory corneal neovascularization: etiopathogenesis.
Clements JL, Dana R.
Semin Ophthalmol. 2011 Jul-Sep;26(4-5):235-45. doi: 10.3109/08820538.2011.588652.
Gene-based antiangiogenic applications for corneal neovascularization.
Liu S, Romano V, Steger B, Kaye SB, Hamill KJ, Willoughby CE.
Surv Ophthalmol. 2018 Mar-Apr;63(2):193-213. doi: 10.1016/j.survophthal.2017.10.006. Epub 2017 Nov 15.
Available Therapeutic Options for Corneal Neovascularization: A Review.
Drzyzga Ł, Śpiewak D, Dorecka M, Wyględowska-Promieńska D.
Int J Mol Sci. 2024 May 17;25(10):5479. doi: 10.3390/ijms25105479.
Recent drug therapies for corneal neovascularization.
Liu X, Wang S, Wang X, Liang J, Zhang Y.
Chem Biol Drug Des. 2017 Nov;90(5):653-664. doi: 10.1111/cbdd.13018. Epub 2017 Jun 21.
Corneal neovascularization: molecular events and therapeutic options.
Shakiba Y, Mansouri K, Arshadi D, Rezaei N.
Recent Pat Inflamm Allergy Drug Discov. 2009 Nov;3(3):221-31. doi: 10.2174/187221309789257450.
[Methods of diagnosis and treatment of corneal neovascularization].
Malyugin BE, Isabekov RS, Kalinnikova SY, Antonova OP.
Vestn Oftalmol. 2023;139(4):86-92. doi: 10.17116/oftalma202313904186.
Corneal neovascularization is inhibited with nucleolin-binding aptamer, AS1411.
Vivanco-Rojas O, García-Bermúdez MY, Iturriaga-Goyon E, Rebollo W, Buentello-Volante B, Magaña-Guerrero FS, Bates P, Pérez-Torres A, Garfias Y.
Exp Eye Res. 2020 Apr;193:107977. doi: 10.1016/j.exer.2020.107977. Epub 2020 Feb 17.
